FDA Peptide Reclassification 2026: What It Means for Providers RFK Jr. forces FDA to reconsider 12 unproven peptides after 2023 ban Ars Technica FDA Category 2 Update: The 5 Peptides Still Facing Heavy Review As excitement builds around peptides potentially moving off the FDA Category 2 list, it's important to understand one key reality: Not Anticipated FDA Approvals for the First Quarter of 2026 Guideline Central